Goldman Sachs’s Taysha Gene Therapies TSHA Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$100M	Buy	22,369,645 +8,676,906	+63%	+$40.3M	0.01%	1025
2025 Q4	$75.3M	Buy	13,692,739 +309,031	+2%	+$1.5M	0.01%	1189
2025 Q3	$43.8M	Buy	13,383,708 +796,008	+6%	+$2.25M	0.01%	1524
2025 Q2	$29.1M	Buy	12,587,700 +12,228,693	+3,406%	+$26.6M	﹤0.01%	1785
2025 Q1	$499K	Sell	359,007 -608,137	-63%	-$1.02M	﹤0.01%	5183
2024 Q4	$1.67M	Sell	967,144 -238,527	-20%	-$495K	﹤0.01%	4444
2024 Q3	$2.42M	Buy	1,205,671 +178,653	+17%	+$392K	﹤0.01%	3987
2024 Q2	$2.3M	Sell	1,027,018 -31,944	-3%	-$93K	﹤0.01%	3817
2024 Q1	$3.04M	Buy	1,058,962 +975,488	+1,169%	+$2.03M	﹤0.01%	3531
2023 Q4	$148K	Buy	+83,474	New	+$166K	﹤0.01%	5227
2023 Q1	–	Sell	-12,127	Closed	-$27.4K	–	6236
2022 Q4	$27.4K	Sell	12,127 -31,356	-72%	-$63.5K	﹤0.01%	5672
2022 Q3	$84K	Sell	43,483 -25,796	-37%	-$93.6K	﹤0.01%	5727
2022 Q2	$258K	Sell	69,279 -19,760	-22%	-$78.4K	﹤0.01%	5504
2022 Q1	$580K	Buy	89,039 +35,991	+68%	+$269K	﹤0.01%	5218
2021 Q4	$618K	Buy	53,048 +40,949	+338%	+$618K	﹤0.01%	5228
2021 Q3	$225K	Buy	+12,099	New	+$230K	﹤0.01%	5670
2021 Q1	–	Sell	-14,763	Closed	-$392K	–	6362
2020 Q4	$392K	Sell	14,763 -63,862	-81%	-$1.38M	﹤0.01%	4753
2020 Q3	$1.76M	Buy	+78,625	New	+$1.85M	﹤0.01%	3653